- Todos > Medicine Information and Evidence for Policy > Medicines Policy
- Todos > Medicine Access and Rational Use > Financing
- Todos > Medicine Access and Rational Use > Pricing
- Palabras clave > access to health
- Palabras clave > access to medicines
- Palabras clave > affordability
- Palabras clave > cost - treatment
- Palabras clave > drug shortages
- Palabras clave > HIV/AIDS-related drugs
- Palabras clave > policy developments
- Palabras clave > price comparison
- Palabras clave > price competition
- Palabras clave > prices / pricing policy
(2011; 13 pages)
The list looks at developments in 2011 that had an impact - whether positive or negative- on people's ability to access needed drugs, diagnostics and vaccines in developing countries.
'For the diseases our medical teams encounter every day in places where we work, 2011 was a year of both critical progress and dangerous backsliding,' said Dr. Tido von Schoen-Angerer, executive director of MSF’s Access Campaign. 'At a time of so much promise, it is crucial to continue pushing forward, and refuse to accept a double standard in care between rich and poor countries.'
The list covers key developments regarding diseases MSF confronts in developing countries: landmark findings about HIV treatment as HIV prevention; the strikingly low number of people receiving treatment for more lethal, drug-resistant forms of tuberculosis; a new subsidy intended to lower the price of malaria treatments that is headed in the wrong direction; a dangerous global shortage of the drug needed to treat the parasitic slow killer Chagas disease; slow progress on better adapting food aid to meet children's needs; vaccine prices finally becoming more transparent; and the first-ever guidelines to treat an HIV-related 'opportunistic infection,' cryptococcal meningitis.
It also looks at key policy developments of the year, including unprecedented funding shortfalls at the Global Fund to Fight AIDS, Tuberculosis and Malaria; drug companies cutting across-the-board discounts in middle-income countries; and the continued struggle to ensure affordable generic medicines can be produced in India, the 'pharmacy of the developing world.'